UK launches H5N1 bird flu vaccine trial to prep for potential pandemic
UK launches H5N1 bird flu vaccine trial to prep for potential pandemic
First UK volunteers receive an H5N1 mRNA vaccine as a 4,000-person trial across 26 sites in England, Scotland and the US, aiming to preempt a future pandemic.
First volunteers in the UK have been immunised with a vaccine to guard against a potential bird flu pandemic. The vaccine targets the H5N1 strain and uses messenger RNA technology similar to Covid vaccines, allowing rapid production at scale for a future outbreak.
The trial plans to enroll around 4,000 volunteers, with most recruitment at 26 sites across England and Scotland and the rest in the United States. The study seeks participants from the poultry industry or people over 65—the groups considered most at risk. The lead investigator says the virus is evolving among animal populations and public health teams must prepare for possible human-to-human transmission. The trial will assess safety and whether the vaccine can curb transmission if a spillover occurs.
The threat to humans remains low, with 116 confirmed human cases around the world since 2024, almost all linked to close contact with infected animals. One of the first volunteers, a Hampshire resident who keeps chickens, was vaccinated at a clinic in Southampton, illustrating local involvement. The initiative underscores a broader push to use mRNA tech beyond Covid-19 for quicker responses to emerging pathogens. If successful, the trial could help shield against future pandemics by enabling faster, scalable vaccine production and deployment.
